Gamma Interferon Pilot Trial Tests Frataxin Boost in Friedreich Ataxia Patients
A Phase 2 open-label trial explores whether an approved immune drug can raise frataxin protein levels and slow neurological decline in Friedreich Ataxia.
Summary
Friedreich Ataxia is a rare inherited disease caused by deficient frataxin protein, leading to progressive neurological damage and heart disease. This Phase 2 pilot trial tested gamma interferon, an already-approved drug for granulomatous disease, in 12 patients over six months to see if it could safely boost frataxin expression and slow disease progression. Building on earlier lab and human studies showing gamma interferon increases frataxin levels, researchers used advanced brain imaging, ataxia rating scales, heart measurements, and retinal scans to track outcomes. Frataxin levels in blood cells were measured at multiple timepoints. The trial was completed by sponsor IRCCS Eugenio Medea, though full results have not yet been published in peer-reviewed literature.
Detailed Summary
Friedreich Ataxia is a devastating inherited neurodegenerative condition caused by mutations in the FXN gene, leading to critically reduced levels of the mitochondrial protein frataxin. The result is progressive loss of coordination, serious heart complications, and significant reduction in life expectancy. No disease-modifying treatment has been approved beyond symptomatic management, making every credible therapeutic lead critically important.
This open-label Phase 2 pilot trial, led by IRCCS Eugenio Medea in Italy, set out to evaluate whether gamma interferon (γIFN) — already approved for chronic granulomatous disease — could safely increase frataxin expression in Friedreich Ataxia patients and slow measurable disease progression. Prior in vitro, animal, and small human studies had demonstrated that γIFN can upregulate frataxin production, providing a pharmacological rationale for this approach.
Twelve patients with molecularly confirmed Friedreich Ataxia were enrolled over six months. Participants received γIFN at 200 micrograms three times per week for six months, with clinical evaluations at three and six months, and a follow-up assessment six months after treatment ended. Frataxin levels in peripheral blood mononuclear cells were tracked throughout. Neuroimaging using 3 Tesla MRI, including functional MRI and tractography, assessed brain changes. Cardiac ventricular wall thickness and retinal nerve fiber layer thickness via optical coherence tomography provided additional biomarkers of disease state.
The trial builds on an earlier observational cohort whose data serves as a historical baseline, giving each patient an estimated 12-month pre-treatment disease trajectory for direct comparison.
Results from this completed trial have not yet appeared in the published literature based on available information. If γIFN proves effective and well tolerated, it could represent a repurposed, near-term treatment option for a condition with few therapeutic choices. The approach of upregulating a deficient endogenous protein via an approved immune modulator is a strategy with broad relevance to other genetic deficiency disorders.
Key Findings
- Gamma interferon was tested as a frataxin-boosting agent in 12 Friedreich Ataxia patients over 6 months.
- The drug is already FDA-approved for granulomatous disease, potentially accelerating any path to clinical use.
- Advanced MRI tractography and functional imaging were used alongside clinical ataxia scales to detect change.
- Retinal nerve fiber layer and cardiac wall thickness served as novel structural biomarkers of disease progression.
- Prior studies in cells, animals, and humans support gamma interferon's ability to increase frataxin levels.
Methodology
Open-label Phase 2 pilot trial enrolling 12 patients with molecularly confirmed Friedreich Ataxia. Participants received gamma interferon 200 mcg three times weekly for six months, with clinical and biomarker assessments at baseline, 3, 6, and 12 months. A pre-existing observational cohort provided historical baseline neuroimaging and clinical data for comparison.
Study Limitations
This summary is based on the abstract and trial registration record only, as full results have not been published in peer-reviewed literature. The open-label design without a placebo control limits the ability to distinguish treatment effects from natural disease variability. The very small sample size of 12 patients means the trial is underpowered for definitive efficacy conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.